FDA Grants Priority Review to Zanubrutinib as Treatment for Mantle Cell Lymphoma
News
The U.S. Food and Drug Administration (FDA) has accepted for review BeiGene‘s application requesting the approval of zanubrutinib for treating people with mantle cell lymphoma who received at least one ... Read more